Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESMO 2024 | PEACE-1: prognostic biomarkers in de novo metastatic prostate cancer

Cedric Pobel • 15 Sep 2024

ESMO 2024

PEACE-1

Cedric Pobel, MD, Gustave Roussy, Villejuif, France, discusses the identification of prognostic biomarkers for radiographic progression-free survival (rPFS) and overall survival (OS) in the PEACE-1 trial (NCT01957436). In patients with metastatic castration-sensitive prostate cancer (mCSPC), neuroendocrine marker positivity was associated with worse outcomes, while ERG positivity correlated with longer radiographic progression-free survival (rPFS). No biomarkers predicted response to abiraterone acetate and prednisone. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.